# Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer

> **NCT00344552** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 53 (actual)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00344552
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2009-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00344552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00344552, "Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00344552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*